About BioReperia
BioReperia is a company based in Stockholm (Sweden) founded in 2015. BioReperia has raised $882.45 thousand across 3 funding rounds from investors including European Union, HEMEX and Almi Invest. BioReperia offers products and services including ZTX ONCOLEADS and ZTX PREDICT. BioReperia operates in a competitive market with competitors including Biocytogen, Interius Biotherapeutics, Applied StemCell, Nagi Bioscience and GemPharmatech, among others.
- Headquarter Stockholm, Sweden
- SectorsHealthcare
- Phone•••• ••••
- Website bioreperia.com
- Social LinkedIn
- Legal Name Bioreperia Ab
- Total Equity Funding$882.45K (USD)
in 3 rounds
- Latest Funding Round$5.64K (USD), Grant
Jan 2021
- InvestorsEuropean Union
& 3 more
Products & Services of BioReperia
BioReperia offers a comprehensive portfolio of products and services, including ZTX ONCOLEADS and ZTX PREDICT.
Enables selection of oncology lead candidates by mimicking tumor environments.
Identifies effective anti-cancer drugs for individual patients quickly.
Funding Insights of BioReperia
BioReperia has successfully raised a total of $882.45K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $5.64 thousand completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $882,454
- Total Rounds 3
- Last Round Grant — $5,641
- First Round $27,933
(Jun 2017)
- Investors Count 4
All 3 funding rounds of BioReperia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $5,641 | Grant | – | – | |
| Jun 2019 | $854,521 | Series A | – | Almi Invest | |
| Jun 2017 | $27,933 | Seed | – | LiU Invest | – |
4 investors in total: 4 institutional.
Investors in BioReperia
BioReperia has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, HEMEX and Almi Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by corporate-backed Almi Invest. | – | almi.se/Almi-Invest/ | Lund, Sweden | |
Regulatory affairs and marketing services are provided for healthcare entities. | 2011 | hemex.ch | Zurich, Switzerland | |
Early-stage investments are made in university-linked innovative companies. | – | liuinvest.se | Linköping, Sweden | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for BioReperia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioReperia
4 people are tracked at BioReperia (3 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Anna Erkstam | Chief Executive Officer | Leadership |
Lasse Jensen | Chief Technology Officer | Leadership |
Marie Waldén | Chief Business Officer | Leadership |
Gabriela Vazquez Rodriguez | Project Management and sales | Team |
Complete people profiles for BioReperia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioReperia
3 dated milestones of BioReperia across 6 years, from founding to its latest funding, stage changes and deals.
- Founded BioReperia is founded.
- Funding First funding round of $28K.
- Funding Latest funding round, Grant, of $6K.
Competitors of BioReperia
BioReperia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Interius Biotherapeutics, Applied StemCell, Nagi Bioscience and GemPharmatech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biocytogen.com | 2008 | Wakefield, United States | $301.11M | 85 | Integrated solutions for next-generation antibody drug development are provided. | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| appliedstemcell.com | 2008 | Milpitas, United States | $67.52M | 53 | Provider of animal and cell line models as tools for drug discovery and diagnostics | |
| nagibio.ch | 2017 | Lausanne, Switzerland | $1.84M | – | Developer of a organism on a chip based technology | |
| gempharmatech.com | 2018 | Nanjing, China | $81.85M | 10 | Humanized models and drug screening technologies are developed for research. | |
| businesscatalyst.com | 2004 | San Jose, United States | $1.25M | 9,771 | In-vivo mouse models are developed for biomedical R&D applications. | |
| lingfubio.tcc.mode | 2021 | Beijing, China | $30.76M | – | Animal research service provider that offers animal behavior analysis services | |
| apceth.com | 2007 | Munich, Germany | – | – | MSC-based therapeutics are developed for cancer, inflammation, and lung diseases. | |
| herabiolabs.com | 2015 | Lexington, United States | $3.39M | – | Provider of rodent models for in vitro and in vivo safety and efficacy testing services |
Detailed competitors of BioReperia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioreperia
Complete news archive for BioReperia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioReperia
10 companies that operate in the same segment as BioReperia (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioReperia
BioReperia was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BioReperia is headquartered in Stockholm, Sweden.
BioReperia is a funded company, having raised a total of $882.45K across 3 funding rounds to date. The company's 1st funding round was a Seed of $27.93K, raised on Jun 2017.
BioReparia develops zebrafish tumor xenograft model by implanting human cells into zebrafish embryo for research application or therapeutic studies. The company can custom design the models based on the users need. The model can be combined with radiation therapy, immune-modulatory therapy, genetic interference or editing, tumor stroma analyses, molecular analyses, ADME analysis and small molecules. Apart from this, it also develops toxicity models of zebrafish for both general and specific toxicity testing.
BioReperia's top competitors include Biocytogen, Applied StemCell and GemPharmatech.
BioReperia offers ZTX ONCOLEADS and ZTX PREDICT.
BioReperia has 4 investors. Key investors include European Union, HEMEX, Almi Invest, and LiU Invest.
BioReperia operates through Bioreperia Ab.